Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Exclusion Criteria

• •1. Laboratory Values
• •* Grade 3 hyperlipidemia (Serum cholesterol \>400mg/dl or serum triglycerides \>5 x ULN)
• •* Serum Glucose \> 250mg/dl on \>/= 2 checks on 2 separate days
• •* Diabetics accepted if sugars controlled
• •2. Unlimited prior chemotherapy regimens, however:
• •* No prior exposure to RAD001 or LBH589 or drugs that target mTOR (sirolimus, temsirolimus, etc) or HDAC (vorinostat)
• •* No valproic acid during study or 5 days preceding start of first drug
• •* No chemotherapy, biologics or immunotherapy \< 2 weeks before registration (6 weeks if last received bis-chloroethylnitrosourea (BCNU) or mitomycin C). Subjects must be recovered from therapy-related non-hematological toxicities to \< grade 1 or baseline if started with \> grade 1 toxicity.
• •* No time limit for radiation prior to registration.
• •* No radioimmunotherapy \< 2 months prior to registration. Subjects must be recovered from therapy-related toxicities to \< grade 1 or baseline if started with \> grade 1 toxicity.
• •* No prior allogeneic stem cell transplantation unless allogeneic engraftment is \<2%.
• •* Subjects receiving chronic, systemic treatment with corticosteroids = to \>20mg of prednisone per day.
• •* Subjects receiving replacement for adrenal insufficiency allowed.
• •* Topical or inhaled corticosteroids allowed.
• •3. History of other primary malignancy \< 3 years ago, except inactive basal, squamous cell carcinoma of the skin or superficial melanoma only requiring excision, prostate cancer with a prostate specific antigen (PSA) stable for \>/=3 months, carcinoma in situ of cervix.
• •4. Major surgery \< 4 weeks before or Minor surgery \< 2 weeks before registration. Subjects must be recovered from toxicities to \< grade 1 or baseline if started with \> grade 1 toxicity.
• •5. Investigational drugs \< 4 weeks prior to registration.
• •6. Impaired Cardiac Function per protocol.
• •7. Pregnant or breastfeeding females or adults of reproductive potential not using effective birth control
• •8. Diffusing capacity or transfer factor of the lung for carbon monoxide (DLCO) \< 40% if tested (per protocol).
• •9. Impaired lung function: O2 saturation 88% or less at rest on room air by Pulse Oximetry.
• •10. Immunization with live attenuated vaccines \< 1 week of study entry
• •11. Impaired GI function or GI disease that may alter absorption of RAD001 or LBH589
• •12. Concurrent severe \&/or uncontrolled medical conditions
• •13. Medications with risk of prolonging QT interval or inducing torsade de pointes or interacting with LBH589 and RAD001 may be used per the protocol.
• •14. Active bleeding tendency
• •15. Positive for HIV.
• •16. Positive for Hepatitis C virus (HCV).
• •17. History of non-compliance to medical regimens.